Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor
Study Identifier:
C10-002
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Eculizumab
Date
Aug 2012 - Jun 2015
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Eculizumab
Date
Aug 2012 - Jun 2015
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information
Protocol Summary
Primary Objective:
To evaluate the safety and potential efficacy of eculizumab to prevent AMR in sensitized recipients of deceased donor kidney transplants.
Trial Locations
Location
Status
Location
Adelaide, Australia, 5000
Status
N/A
Location
Camperdown, Australia, 2050
Status
N/A
Location
Parkville, Australia, 3050
Status
N/A
Location
Bordeaux, France, 33076
Status
N/A
Location
Paris, France, 75010
Status
N/A
Location
Paris, France, 75743
Status
N/A